Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report)’s share price was up 11.3% during trading on Wednesday. The stock traded as high as $4.09 and last traded at $4.2730. 260,194 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 3,383,160 shares. The stock had previously closed at $3.84.
Prime Medicine News Roundup
Here’s some of the latest news about PRME:
- Positive Sentiment: HC Wainwright raised its EPS estimates for multiple periods, including FY2026 to a loss of $0.99 per share from $1.11, and FY2027 to a loss of $0.89 from $0.91. The firm maintained its Buy rating and $8 price target. Prime Medicine coverage
- Positive Sentiment: HC Wainwright’s Buy rating was also reaffirmed, providing continued analyst support for PRME. Prime Medicine rating reaffirmed
- Neutral Sentiment: Prime Medicine presented at the Jefferies Global Healthcare Conference; the supplied article entry does not describe specific announcements or new data. Jefferies conference transcript
Analysts Set New Price Targets
A number of equities analysts have commented on PRME shares. BMO Capital Markets began coverage on shares of Prime Medicine in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Prime Medicine in a report on Friday, September 25th. Jefferies Financial Group restated a “market outperform” rating on shares of Prime Medicine in a report on Monday, September 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prime Medicine in a research report on Monday, August 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Prime Medicine in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.86.
View Our Latest Stock Report on Prime Medicine
Prime Medicine Price Performance
The business has a 50-day moving average of $3.71 and a two-hundred day moving average of $3.51. The company has a market cap of $717.67 million, a P/E ratio of -4.09 and a beta of 2.14.
Prime Medicine (NASDAQ:PRME – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. The company had revenue of $4.21 million during the quarter. Equities analysts anticipate that Prime Medicine, Inc. will post -0.97 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of PRME. Bank of America Corp DE purchased a new position in Prime Medicine in the second quarter valued at $3,621,000. BlackRock Inc. purchased a new position in shares of Prime Medicine in the second quarter valued at approximately $35,432,000. Alphabet Inc. acquired a new stake in shares of Prime Medicine in the second quarter valued at about $61,116,000. Redmile Group LLC purchased a new position in Prime Medicine in the 1st quarter worth approximately $5,536,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Prime Medicine in the second quarter valued at about $7,371,000. 70.37% of the stock is owned by institutional investors and hedge funds.
About Prime Medicine
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
See Also
- Five stocks we like better than Prime Medicine
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
